Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen Opat

Showing results (81-90 of 124) with videos related to

Pageof 13
Sort By:
Haematologica|September 25, 2025
Prognostic value of tumor bulk in modern management of common lymphoma subtypes: an Australasian Lymphoma and Related Diseases Registry studyEliza Chung, Luke Wang, Cameron Wellard, et al.
Leukemia & Lymphoma|February 20, 2024
Australian experience with ibrutinib in patients with relapsed/refractory mantle cell lymphoma: a study from the Lymphoma and Related Diseases RegistryDiva Baggio, Cameron Wellard, Eliza Chung, et al.
American Journal of Hematology|March 23, 2021
WhiMSICAL: A global Waldenström's Macroglobulinemia patient-derived data registry capturing treatment and quality of life outcomesIbrahim Tohidi-Esfahani, Andrew Warden, Elena Malunis, et al.
Blood|July 23, 2020
Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-upJudith Trotman, Stephen Opat, David Gottlieb, et al.
Internal Medicine Journal|July 8, 2024
Australians with chronic lymphocytic leukaemia continue to have high rates of second primary malignancies in the modern eraDiva Baggio, Eliza Chung, Cameron Wellard, et al.
The Lancet. Oncology|October 9, 2020
Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trialFranck Morschhauser, Hervé Tilly, Aristeidis Chaidos, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|October 13, 2023
A Population-Based Family Case-Control Study of Sun Exposure and Follicular Lymphoma RiskMichael K Odutola, Marina T van Leeuwen, Fiona Bruinsma, et al.
Hemasphere|June 19, 2026
Phase 3 PERSPECTIVE study: Ibrutinib with rituximab for initial treatment of patients with follicular lymphomaDavid Belada, Faithlore P Gardner, Ana C de Oliveira, et al.
Blood|January 3, 2012
Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphomaRobert Kridel, Barbara Meissner, Sanja Rogic, et al.
Internal Medicine Journal|March 7, 2025
Ratifying the efficacy and safety of intensive induction chemotherapy for acute myeloid leukaemia by the Australasian Leukaemia & Lymphoma Group consensus approachAditya Tedjaseputra, Amanda Tey, Anastasios Nalpantidis, et al.
Pageof 13

Showing results (81-90 of 124) with videos related to

Sort By:
Pageof 13
Haematologica|September 25, 2025
Prognostic value of tumor bulk in modern management of common lymphoma subtypes: an Australasian Lymphoma and Related Diseases Registry studyEliza Chung, Luke Wang, Cameron Wellard, et al.
Leukemia & Lymphoma|February 20, 2024
Australian experience with ibrutinib in patients with relapsed/refractory mantle cell lymphoma: a study from the Lymphoma and Related Diseases RegistryDiva Baggio, Cameron Wellard, Eliza Chung, et al.
American Journal of Hematology|March 23, 2021
WhiMSICAL: A global Waldenström's Macroglobulinemia patient-derived data registry capturing treatment and quality of life outcomesIbrahim Tohidi-Esfahani, Andrew Warden, Elena Malunis, et al.
Blood|July 23, 2020
Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-upJudith Trotman, Stephen Opat, David Gottlieb, et al.
Internal Medicine Journal|July 8, 2024
Australians with chronic lymphocytic leukaemia continue to have high rates of second primary malignancies in the modern eraDiva Baggio, Eliza Chung, Cameron Wellard, et al.
The Lancet. Oncology|October 9, 2020
Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trialFranck Morschhauser, Hervé Tilly, Aristeidis Chaidos, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|October 13, 2023
A Population-Based Family Case-Control Study of Sun Exposure and Follicular Lymphoma RiskMichael K Odutola, Marina T van Leeuwen, Fiona Bruinsma, et al.
Hemasphere|June 19, 2026
Phase 3 PERSPECTIVE study: Ibrutinib with rituximab for initial treatment of patients with follicular lymphomaDavid Belada, Faithlore P Gardner, Ana C de Oliveira, et al.
Blood|January 3, 2012
Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphomaRobert Kridel, Barbara Meissner, Sanja Rogic, et al.
Internal Medicine Journal|March 7, 2025
Ratifying the efficacy and safety of intensive induction chemotherapy for acute myeloid leukaemia by the Australasian Leukaemia & Lymphoma Group consensus approachAditya Tedjaseputra, Amanda Tey, Anastasios Nalpantidis, et al.
Pageof 13